JP2019516711A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516711A5 JP2019516711A5 JP2018560520A JP2018560520A JP2019516711A5 JP 2019516711 A5 JP2019516711 A5 JP 2019516711A5 JP 2018560520 A JP2018560520 A JP 2018560520A JP 2018560520 A JP2018560520 A JP 2018560520A JP 2019516711 A5 JP2019516711 A5 JP 2019516711A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- riluzole
- checkpoint inhibitor
- drug according
- msr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 13
- 229960004181 riluzole Drugs 0.000 claims 13
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 10
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 10
- 229940000425 combination drug Drugs 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 230000004083 survival effect Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 229940124650 anti-cancer therapies Drugs 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 229960005386 ipilimumab Drugs 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 229960003301 nivolumab Drugs 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229950007213 spartalizumab Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022173334A JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339433P | 2016-05-20 | 2016-05-20 | |
| US62/339,433 | 2016-05-20 | ||
| PCT/US2017/033688 WO2017201501A1 (en) | 2016-05-20 | 2017-05-19 | Use of riluzole, riluzole prodrugs or riluzole analogs with immunotherapies to treat cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022173334A Division JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516711A JP2019516711A (ja) | 2019-06-20 |
| JP2019516711A5 true JP2019516711A5 (enExample) | 2020-06-11 |
| JP7169195B2 JP7169195B2 (ja) | 2022-11-10 |
Family
ID=60326148
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560520A Active JP7169195B2 (ja) | 2016-05-20 | 2017-05-19 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
| JP2018560528A Active JP7224186B2 (ja) | 2016-05-20 | 2017-05-19 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022150358A Active JP7653398B2 (ja) | 2016-05-20 | 2022-09-21 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022173334A Active JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560528A Active JP7224186B2 (ja) | 2016-05-20 | 2017-05-19 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022150358A Active JP7653398B2 (ja) | 2016-05-20 | 2022-09-21 | 癌を処置するためのグルタミン酸調節剤と免疫療法の併用 |
| JP2022173334A Active JP7493569B2 (ja) | 2016-05-20 | 2022-10-28 | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US11400155B2 (enExample) |
| EP (3) | EP3458053B1 (enExample) |
| JP (4) | JP7169195B2 (enExample) |
| KR (2) | KR102525527B1 (enExample) |
| CN (2) | CN109890387B (enExample) |
| AU (2) | AU2017266951B2 (enExample) |
| CA (1) | CA3025019A1 (enExample) |
| CY (1) | CY1124999T1 (enExample) |
| DK (2) | DK3458053T3 (enExample) |
| EA (1) | EA201892587A1 (enExample) |
| ES (3) | ES2905823T3 (enExample) |
| FI (1) | FI4019019T3 (enExample) |
| HR (2) | HRP20240617T1 (enExample) |
| HU (2) | HUE058184T2 (enExample) |
| IL (2) | IL292302B2 (enExample) |
| LT (2) | LT3458053T (enExample) |
| MX (2) | MX2018013868A (enExample) |
| PH (1) | PH12018502409A1 (enExample) |
| PL (2) | PL4019019T3 (enExample) |
| PT (2) | PT3458053T (enExample) |
| RS (2) | RS62935B1 (enExample) |
| SG (1) | SG11201809669RA (enExample) |
| SI (2) | SI4019019T1 (enExample) |
| SM (1) | SMT202400174T1 (enExample) |
| WO (2) | WO2017201501A1 (enExample) |
| ZA (1) | ZA201807398B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013138753A1 (en) * | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
| JP6700293B2 (ja) * | 2015-03-03 | 2020-05-27 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | リルゾールプロドラッグおよびそれらの使用 |
| SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| CN114591433A (zh) | 2015-07-13 | 2022-06-07 | 西托姆克斯治疗公司 | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 |
| JP6971239B2 (ja) | 2015-10-05 | 2021-11-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法 |
| LT3458053T (lt) * | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
| JP7373991B2 (ja) | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| TW202436356A (zh) | 2016-10-11 | 2024-09-16 | 美商艾吉納斯公司 | 抗ｌａｇ－３抗體及其使用方法 |
| KR20240019398A (ko) * | 2016-10-28 | 2024-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 요로상피 암종을 치료하는 방법 |
| US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| WO2020023324A1 (en) * | 2018-07-22 | 2020-01-30 | Biohaven Therapeutics Ltd. | Use of riluzole prodrugs to treat alzheimer's disease |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
| US20210177841A1 (en) * | 2017-11-03 | 2021-06-17 | Calithera Biosciences, Inc. | Conjoint therapy with glutaminase inhibitors |
| US10751345B2 (en) | 2018-02-21 | 2020-08-25 | AI Therapeutics, Inc. | Combination therapy with apilimod and glutamatergic agents |
| CN111741978A (zh) | 2018-02-21 | 2020-10-02 | 戊瑞治疗有限公司 | B7-h4抗体制剂 |
| EP3759142A1 (en) | 2018-03-02 | 2021-01-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| EP3914266A4 (en) * | 2019-01-24 | 2022-12-07 | University of Cincinnati | AUTOLOGOUS TUMORORGANOID AND IMMUNE CELL COCULTURES AND METHODS FOR USE AS PREDICTIVE MODELS FOR TREATMENT OF PANCREA CANCER |
| CA3141405A1 (en) * | 2019-06-12 | 2020-12-17 | H. Charles Manning | Amino acid transport inhibitors and the uses thereof |
| CN110646557A (zh) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途 |
| MX2022011409A (es) * | 2020-03-17 | 2022-12-02 | Ohio State Innovation Foundation | Vesiculas extracelulares de diseño para tratar la excitotoxicidad. |
| KR102441650B1 (ko) * | 2020-07-31 | 2022-09-08 | 서울대학교병원 | 다중약물 화학요법에 있어서 항암제의 유효 용량 정보의 제공 방법 |
| WO2022197767A1 (en) * | 2021-03-17 | 2022-09-22 | Memorial Sloan-Kettering Cancer Center | Methods for improving survival in lung cancer patients via ketamine oncoprotection |
| WO2023003972A1 (en) * | 2021-07-21 | 2023-01-26 | Viracta Subsidiary, Inc. | Cancer treatment combinations |
| WO2023202652A1 (en) * | 2022-04-21 | 2023-10-26 | Jacobio Pharmaceuticals Co., Ltd. | Pharmaceutical combination and use thereof |
| CN116492322A (zh) * | 2023-05-10 | 2023-07-28 | 徐州医科大学 | 小分子阻滞剂mem在制备治疗肿瘤药物的应用 |
| CN119174765A (zh) * | 2024-09-04 | 2024-12-24 | 复旦大学附属中山医院 | Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用 |
Family Cites Families (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7812A (en) | 1850-12-03 | Nail-plate feeder and turner | ||
| CA209066A (en) | 1921-03-01 | Tschirner Frederick | Conversion of potassium to soluble state | |
| US135A (en) | 1837-03-03 | Jesse j | ||
| US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
| US6362325B1 (en) | 1988-11-07 | 2002-03-26 | Advanced Research And Technology Institute, Inc. | Murine 4-1BB gene |
| US6355476B1 (en) | 1988-11-07 | 2002-03-12 | Advanced Research And Technologyinc | Nucleic acid encoding MIP-1α Lymphokine |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US5631023A (en) | 1993-07-09 | 1997-05-20 | R.P. Scherer Corporation | Method for making freeze dried drug dosage forms |
| US5457895A (en) | 1993-10-01 | 1995-10-17 | R. P. Scherer Corporation | Method of identifying freeze-dried dosage forms |
| US5837287A (en) | 1994-10-28 | 1998-11-17 | R P Scherer Corporation | Process for preparing solid pharmaceutical dosage forms |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7727761B2 (en) | 1995-08-01 | 2010-06-01 | Vegenics Limited | Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| HUP9904697A3 (en) | 1996-10-11 | 2001-06-28 | Bristol Myers Squibb Company P | Methods and compositions for immunomodulation |
| ATE421318T1 (de) | 1997-02-20 | 2009-02-15 | Massachusetts Inst Technology | Darreichungsform, welche rasche dispersionseigenschaften entfaltet, anwendungsverfahren sowie verfahren zur herstellung derselben |
| KR100870353B1 (ko) | 1997-04-07 | 2008-11-25 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2263216T3 (es) | 1997-07-25 | 2006-12-01 | Alpex Pharma S.A. | Procedimiento para la preparacion de un granulado adecuado para la preparacion de comprimidos solubles en la boca rapidamente disgregables. |
| IL143197A0 (en) | 1998-11-20 | 2002-04-21 | Rtp Pharma Inc | Dispersible phospholipid stabilized microparticles |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| ES2466715T3 (es) | 1999-06-25 | 2014-06-11 | Immunogen, Inc. | Métodos de tratamiento usando conjugados de anticuerpo anti-ErbB-maitansinoide |
| US6284270B1 (en) | 1999-08-04 | 2001-09-04 | Drugtech Corporation | Means for creating a mass having structural integrity |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US6814978B2 (en) | 2000-12-29 | 2004-11-09 | Mcneil-Ppc, Inc. | Process for preparing a soft tablet |
| US6509040B1 (en) | 2001-06-22 | 2003-01-21 | R.P. Scherer Corporation | Fast dispersing dosage forms essentially free of mammalian gelatin |
| EP1443912B1 (en) | 2001-10-12 | 2007-08-29 | Elan Pharma International Limited | Compositions having a combination of immediate release and controlled release characteristics |
| WO2003068604A1 (en) | 2002-02-13 | 2003-08-21 | Weibel Michael K | Drug dose-form and method of manufacture |
| ATE475431T1 (de) | 2002-03-04 | 2010-08-15 | Imclone Llc | Kdr-spezifische humane antikörper und deren anwendung |
| WO2004010947A2 (en) | 2002-07-30 | 2004-02-05 | Bristol-Myers Squibb Company | Humanized antibodies against human 4-1bb |
| KR101420344B1 (ko) | 2003-07-02 | 2014-07-16 | 위니베르시따 디 제노바 | Ｐａｎ-ｋｉｒ2ｄｌ ｎｋ-수용체 항체 및 진단 및 치료에서의 그 사용 방법 |
| EP2292264A3 (en) | 2003-07-24 | 2012-12-19 | Innate Pharma | Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds |
| US7282217B1 (en) | 2003-08-29 | 2007-10-16 | Kv Pharmaceutical Company | Rapidly disintegrable tablets |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| DK2287195T3 (da) | 2004-07-01 | 2019-08-19 | Innate Pharma | Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi |
| NZ552946A (en) | 2004-08-26 | 2010-09-30 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| BRPI0513915A (pt) | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
| DK1819358T3 (da) | 2004-11-18 | 2014-10-27 | Imclone Llc | Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1 |
| WO2006072625A2 (en) | 2005-01-06 | 2006-07-13 | Novo Nordisk A/S | Anti-kir combination treatments and methods |
| SI1836225T1 (sl) | 2005-01-06 | 2012-06-29 | Novo Nordisk As | Kir vezujoäśa sredstva in postopki za njihovo rabo |
| WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| EP1744020A1 (de) | 2005-07-14 | 2007-01-17 | Siemens Aktiengesellschaft | Verfahren zum Starten einer Dampfturbinenanlage |
| JP5419067B2 (ja) | 2005-10-14 | 2014-02-19 | イナート・ファルマ・ソシエテ・アノニム | 増殖性障害を処置するための組成物および方法 |
| US8158152B2 (en) | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
| RU2387650C2 (ru) | 2005-12-05 | 2010-04-27 | Пфайзер Продактс Инк. | Полиморфы с-met/hgfr ингибитора |
| DK1959955T3 (da) | 2005-12-05 | 2011-02-07 | Pfizer Prod Inc | Fremgangsmåde til behandling af abnorm cellevækst |
| WO2007074472A2 (en) | 2005-12-27 | 2007-07-05 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| EA018573B1 (ru) | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| CN101578113B (zh) | 2007-01-11 | 2015-04-22 | 诺和诺德公司 | 抗-kir抗体、制剂及其应用 |
| JP2008278814A (ja) | 2007-05-11 | 2008-11-20 | Igaku Seibutsugaku Kenkyusho:Kk | アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用 |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| EP2170282A4 (en) | 2007-06-27 | 2014-11-05 | Hanmi Pharm Ind Co Ltd | METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION |
| CA2693677C (en) | 2007-07-12 | 2018-02-13 | Tolerx, Inc. | Combination therapies employing gitr binding molecules |
| CA2700860C (en) | 2007-10-01 | 2016-07-19 | Jonathan A. Terrett | Human antibodies that bind mesothelin, and uses thereof |
| MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
| TW200938224A (en) | 2007-11-30 | 2009-09-16 | Medarex Inc | Anti-B7H4 monoclonal antibody-drug conjugate and methods of use |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| US8849441B2 (en) | 2008-10-31 | 2014-09-30 | The Invention Science Fund I, Llc | Systems, devices, and methods for making or administering frozen particles |
| US8603496B2 (en) | 2008-10-31 | 2013-12-10 | The Invention Science Fund I, Llc | Compositions and methods for biological remodeling with frozen particle compositions |
| US8709411B2 (en) | 2008-12-05 | 2014-04-29 | Novo Nordisk A/S | Combination therapy to enhance NK cell mediated cytotoxicity |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| RU2595409C2 (ru) | 2009-09-03 | 2016-08-27 | Мерк Шарп И Доум Корп., | Анти-gitr-антитела |
| US8313768B2 (en) | 2009-09-24 | 2012-11-20 | Mcneil-Ppc, Inc. | Manufacture of tablet having immediate release region and sustained release region |
| FR2957077B1 (fr) * | 2010-03-02 | 2012-04-13 | Univ Dauvergne Clermont I | Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux |
| MX339621B (es) | 2010-04-13 | 2016-06-02 | Celldex Therapeutics Inc * | Anticuerpos que se unen a cd27 humano y uso de los mismos. |
| WO2011152351A1 (ja) | 2010-05-31 | 2011-12-08 | 小野薬品工業株式会社 | プリノン誘導体 |
| EP4640281A3 (en) * | 2010-10-13 | 2026-01-07 | Celex Oncology Innovations Limited | Inhibition of metastasis by compounds which reduce the persistent part of the voltage-gated sodium channel |
| CA2818684C (en) | 2010-11-22 | 2023-02-21 | Innate Pharma Sa | Nk cell modulating treatments and methods for treatment of hematological malignancies |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| TWI560200B (en) | 2011-05-25 | 2016-12-01 | Innate Pharma Sa | Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders |
| WO2013017989A1 (en) | 2011-08-02 | 2013-02-07 | Pfizer Inc. | Crizotinib for use in the treatment of cancer |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| US9041556B2 (en) | 2011-10-20 | 2015-05-26 | Apple Inc. | Method for locating a vehicle |
| AU2012335553B2 (en) | 2011-11-09 | 2017-09-21 | Bristol-Myers Squibb Company | Treatment of hematologic malignancies with an anti-CXCR4 antibody |
| US10864271B2 (en) * | 2012-02-15 | 2020-12-15 | Rutgers, The State University Of New Jersey | Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation |
| WO2013138753A1 (en) | 2012-03-16 | 2013-09-19 | Fox Chase Chemical Diversity Center, Inc. | Prodrugs of riluzole and their method of use |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| KR101566538B1 (ko) | 2012-06-08 | 2015-11-05 | 국립암센터 | 신규한 Ｔｈ17 세포 전환용 에피토프 및 이의 용도 |
| WO2013192610A2 (en) | 2012-06-23 | 2013-12-27 | Fox Chase Chemical Diversity Center, Inc. | Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| KR102130865B1 (ko) | 2012-10-02 | 2020-08-05 | 브리스톨-마이어스 스큅 컴퍼니 | 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
| SI3508502T1 (sl) | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| CN103536594A (zh) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途 |
| WO2015061752A1 (en) | 2013-10-25 | 2015-04-30 | Pharmacyclics, Inc. | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
| AU2015266958A1 (en) | 2014-05-28 | 2016-12-08 | Agenus Inc. | Anti-GITR antibodies and methods of use thereof |
| BR112017000497B1 (pt) * | 2014-07-11 | 2023-12-26 | Ventana Medical Systems, Inc | Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1 |
| US10392444B2 (en) * | 2014-08-08 | 2019-08-27 | Oncoquest, Inc. | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| US20160073759A1 (en) * | 2014-09-15 | 2016-03-17 | Beauty Solutions Agency Inc. | Nail covering |
| JP7305300B2 (ja) * | 2014-11-05 | 2023-07-10 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 併用免疫療法 |
| EP3221859B1 (en) * | 2014-11-18 | 2020-10-21 | Maximum Fidelity Surgical Simulations, LLC | Post mortem reconstitution of circulation |
| US20160140879A1 (en) * | 2014-11-19 | 2016-05-19 | David Hananel | Anatomically correct movement or deformation of simulated bodily structures |
| US11911369B2 (en) * | 2015-03-03 | 2024-02-27 | Biohaven Therapeutics Ltd. | Prodrugs of riluzole and their method of use |
| JP6700293B2 (ja) * | 2015-03-03 | 2020-05-27 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッドＢｉｏｈａｖｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｈｏｌｄｉｎｇ Ｃｏｍｐａｎｙ Ｌｔｄ． | リルゾールプロドラッグおよびそれらの使用 |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| TW201725044A (zh) | 2015-10-01 | 2017-07-16 | 基利科學股份有限公司 | 用於治療癌症之btk抑制劑及查核點抑制劑之組合 |
| LT3458053T (lt) | 2016-05-20 | 2022-02-25 | Biohaven Pharmaceutical Holding Company Ltd. | Riluzolo, rilizolo provaistų arba riluzolo analogų panaudojimas kartu su imunoterapijomis vėžio formų gydymui |
-
2017
- 2017-05-19 LT LTEPPCT/US2017/033688T patent/LT3458053T/lt unknown
- 2017-05-19 KR KR1020227006275A patent/KR102525527B1/ko active Active
- 2017-05-19 WO PCT/US2017/033688 patent/WO2017201501A1/en not_active Ceased
- 2017-05-19 DK DK17800310.9T patent/DK3458053T3/da active
- 2017-05-19 HU HUE17800310A patent/HUE058184T2/hu unknown
- 2017-05-19 DK DK21207246.6T patent/DK4019019T3/da active
- 2017-05-19 MX MX2018013868A patent/MX2018013868A/es unknown
- 2017-05-19 HR HRP20240617TT patent/HRP20240617T1/hr unknown
- 2017-05-19 PT PT178003109T patent/PT3458053T/pt unknown
- 2017-05-19 WO PCT/US2017/033690 patent/WO2017201502A1/en not_active Ceased
- 2017-05-19 PL PL21207246.6T patent/PL4019019T3/pl unknown
- 2017-05-19 SM SM20240174T patent/SMT202400174T1/it unknown
- 2017-05-19 HR HRP20220237TT patent/HRP20220237T1/hr unknown
- 2017-05-19 ES ES17800310T patent/ES2905823T3/es active Active
- 2017-05-19 PL PL17800310T patent/PL3458053T3/pl unknown
- 2017-05-19 US US16/302,284 patent/US11400155B2/en active Active
- 2017-05-19 JP JP2018560520A patent/JP7169195B2/ja active Active
- 2017-05-19 EA EA201892587A patent/EA201892587A1/ru unknown
- 2017-05-19 RS RS20220165A patent/RS62935B1/sr unknown
- 2017-05-19 KR KR1020187036485A patent/KR102369735B1/ko active Active
- 2017-05-19 FI FIEP21207246.6T patent/FI4019019T3/fi active
- 2017-05-19 SI SI201731511T patent/SI4019019T1/sl unknown
- 2017-05-19 ES ES21207246T patent/ES2981830T3/es active Active
- 2017-05-19 CA CA3025019A patent/CA3025019A1/en active Pending
- 2017-05-19 IL IL292302A patent/IL292302B2/en unknown
- 2017-05-19 PT PT212072466T patent/PT4019019T/pt unknown
- 2017-05-19 CN CN201780044939.XA patent/CN109890387B/zh active Active
- 2017-05-19 HU HUE21207246A patent/HUE066655T2/hu unknown
- 2017-05-19 RS RS20240502A patent/RS65474B1/sr unknown
- 2017-05-19 EP EP17800310.9A patent/EP3458053B1/en active Active
- 2017-05-19 EP EP17800311.7A patent/EP3458054B1/en active Active
- 2017-05-19 JP JP2018560528A patent/JP7224186B2/ja active Active
- 2017-05-19 SG SG11201809669RA patent/SG11201809669RA/en unknown
- 2017-05-19 SI SI201731061T patent/SI3458053T1/sl unknown
- 2017-05-19 CN CN202210573206.8A patent/CN115350263A/zh active Pending
- 2017-05-19 US US16/302,270 patent/US12383619B2/en active Active
- 2017-05-19 LT LTEP21207246.6T patent/LT4019019T/lt unknown
- 2017-05-19 ES ES17800311T patent/ES2912131T3/es active Active
- 2017-05-19 AU AU2017266951A patent/AU2017266951B2/en active Active
- 2017-05-19 EP EP21207246.6A patent/EP4019019B1/en active Active
-
2018
- 2018-11-05 ZA ZA2018/07398A patent/ZA201807398B/en unknown
- 2018-11-07 IL IL262849A patent/IL262849B/en unknown
- 2018-11-12 MX MX2022010377A patent/MX2022010377A/es unknown
- 2018-11-15 PH PH12018502409A patent/PH12018502409A1/en unknown
-
2021
- 2021-08-25 AU AU2021221560A patent/AU2021221560B2/en active Active
-
2022
- 2022-02-16 CY CY20221100131T patent/CY1124999T1/el unknown
- 2022-08-01 US US17/878,121 patent/US20230310595A1/en active Pending
- 2022-09-21 JP JP2022150358A patent/JP7653398B2/ja active Active
- 2022-10-28 JP JP2022173334A patent/JP7493569B2/ja active Active
-
2025
- 2025-08-12 US US19/297,799 patent/US20250360208A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516711A5 (enExample) | ||
| Bedke et al. | Updated European Association of Urology guidelines on renal cell carcinoma: nivolumab plus cabozantinib joins immune checkpoint inhibition combination therapies for treatment-naïve metastatic clear-cell renal cell carcinoma | |
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2019536805A5 (enExample) | ||
| JP2017504611A5 (enExample) | ||
| FI3377534T3 (fi) | Keuhkosyövän hoito käyttäen anti-pd-1-vasta-aineen ja anti-ctla-4-vasta-aineen yhdistelmää | |
| JP2019065028A5 (enExample) | ||
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| JP2018508593A5 (enExample) | ||
| JP2018109022A5 (enExample) | ||
| Nemunaitis et al. | Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JP2014132009A5 (enExample) | ||
| JP2016529285A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| Yoon et al. | Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib | |
| JP2016525097A5 (enExample) | ||
| JP2019532047A5 (enExample) | ||
| CA2922684A1 (en) | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases | |
| JP2019508476A5 (enExample) | ||
| Ramaswamy et al. | A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors | |
| Denlinger et al. | A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers | |
| JP2019530706A5 (enExample) | ||
| Suder et al. | A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours | |
| JP2021505669A5 (enExample) |